Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Preparation and Evaluation of Non-Crystalline Cefuroxime Axetil Solid Dispersion

비결정성 세푸록심 악세틸 고체분산체의 제조 및 평가

  • Woo, Jong-Soo (Department of Pharmceutical R&D, Hanmi Pharm. Co., Ltd.) ;
  • Chang, Hee-Chul (Department of Pharmceutical R&D, Hanmi Pharm. Co., Ltd.) ;
  • Lee, Chang-Hyun (Department of Pharmceutical R&D, Hanmi Pharm. Co., Ltd.)
  • Published : 2002.06.20
Download PDF
⟨ Previous Next ⟩

Abstract

Cefuroxime axetil is a cephalosporin antibiotic having a high activity against a wide spectrum of Grampositive and Gram-negative microorganisms. It is a cephalosporin antibiotic which exist as 2 diastereoisomers: diastereoisomer A and B. It shows polymorphism of three forms: a crystalline form having a melting point of about $180^{\circ}C$, a substantially amorphous form having a high melting point of about $135^{\circ}C$ and a substantially amorphous form having a low melting point of about 70^{\circ}C$. The crystalline form of cefuroxime axetil is slightly soluble in water because diastereoisomer A has lower solubility than B in water. Substantially amorphous form of which there are no difference in solubility between diastereoisomer A and B has better solubility than crystalline form, but it forms a thicker gel than crystalline form upon contact with an aqueous medium. Based on this reason, cefuroxime axetil is not readily absorbable in the gastrointestinal tract, rendering its bioavailability on oral administration very low. The object of this study was to develop an improved non-crystalline cefuroxime axetil composition having a high physicochemical stability and bioavailability. A non-crystalline cefuroxime axetil solid dispersant showing no peak on a Differential Scanning Calorimetry (DSC) scan is prepared by dissolving cefuroxime axetil and a surfactant in an organic solvent; suspending a water-insoluble inorganic carrier in the resulting solution; and spray drying the resulting suspension to remove the organic solvent, said solid dispersant having an enhanced dissolution and stability of cefuroxime axetil and being useful for the preparation of a pharmaceutical composition for oral administration. Tablet was formulated with this cefuroxime axetil solid dispersant, disintegrants and other ingredients. It disintegrated and dissolved easily and dynamically in dissolution medium, so showed a good dissolution profile.

Keywords

References

  1. Harding S.M., Wiliams P.E.O., Ayrton J. Pharmacology of cefuroxime as the 1-acetoxyethyl ester in volunteers, Antimicrob. Agents Chemother., 25, 78-82 (1984) https://doi.org/10.1128/AAC.25.1.78
  2. Emmerson A. M., Cefuroxime axetil, J. Antimicrob. Chem other., 22, 101-103 (1988) https://doi.org/10.1093/jac/22.2.101
  3. Dellamonica P., Cefuroxime axetil, Int J. Antimicrob. Agents., 4, 23-26 (1994) https://doi.org/10.1016/0924-8579(94)90061-2
  4. Oszczapowicz, I., Tejchman, B., Ziminiak, A. and Oszcza- powicz, J., Esters of cephalosporins. Part VI. Properties of the -form of 1-acetoxyethyl ester of cefuroxime, Acta Poloniae Pharmaceutica., 55, 3, 197-204 (1998)
  5. Oszczapowicz, I., Malafiej, E., Horoszewicz-Malafiej, A., Szelachowska, M., Kuklewicz, C. and Sieranska, E., Esters of cephalosporins. Part III. Separation and properties of the R and S isomers of the 1-acetoxyethyl ester of cefuroxime, Acta Poloniae Pharmaceutica., 52, 6, 471-476 (1995)
  6. USP XXIV, 2000, p.355-356
  7. Pharmaceutical compositions, US patent 4,897,270 (1990)
  8. A. Burger and K. T. Koller, Polymorphism and pseudopoly- morphism on nifedifine, Sci. Pharm., 64, 293-301 (1996)
  9. H. Zhu, B. E. Padden, E. J. Munson and D. J. W. Grant, Physicochemical characterization of nedocromil bivalent metal salt hydrate. 2. Nedocromil zinc, J. Pharm. Sci., 86, 418-429 (1997) https://doi.org/10.1021/js9604422
  10. A. David, E. Balogh, G. Csoka and I. Racz, Methodological aspects of examination of the polymorphism of vincristine sulfate, Sci. Pharm., 64, 311-318 (1996)
  11. M. R. Caira, M. Zanol, t. Peveri, A. Gazzaniga and F. Gior- dano, Structural characterization of two polymorphic forms of piroxicam pivalate, J. Pharm. Sci., 87, 1608-1614 (1998) https://doi.org/10.1021/js980059s
  12. Ahlheck, C., and G. Zografi. The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid state. Int. J. Pharm., 62, 87 -95 (1990) https://doi.org/10.1016/0378-5173(90)90221-O
  13. Process for the preparation of cefuroxime axetil in an amorphous form, WO patent 99/65919 (1999)
  14. Oszczapowicz, I., Malafiej, E., Szelachowska, M., Horosze- wicz-malafiej, A. Kuklewicz, C., Sieranska, E., Denys, A. and Niedworok, J. Esters of cephalosporins. Part II. Differences in the properties of various forms of the 1-acetoxyethyl ester of cefuroxime. Acta Poloniae Pharmaceutica, 52, 5, 397-401 (1995)
  15. R. A. Lodder, M. Selby, and G. M. Hieftje, Detection of capsule tampering by Near-Infrared Reflectance analysis, Anal. Chem., 59, 1921-1930 (1987) https://doi.org/10.1021/ac00142a008
  16. P. J. Gemperline and L. D. Webber, Raw materials testing using soft independent modeling of class analogy analysis of Near-Infrared Reflectance spectra. Anal. Chem., 61, 138-144 (1989) https://doi.org/10.1021/ac00177a012
  17. J. W. Moore and H. H. Flanner, Mathematical comparison of curves with an emphasis on in vitro dissolution profiles. Pharm. Tech., 20, 6, 64-74 (1996)
  18. V. P. Shah, Y. Tsong and P. Sathe, In vitro dissolution profile comparison statistics and analysis of the similarity factor, f2. Pharm. Res., 15, 889-896 (1998) https://doi.org/10.1023/A:1011976615750